<DOC>
	<DOCNO>NCT01157988</DOCNO>
	<brief_summary>This phase II study aim clinical efficacy toxicity 6th R-CHOP chemotherapy follow ibritumomab tiuxetan ( Zevalin ) consolidation patient limited-stage , bulky diffuse large B cell lymphoma ( DLBCL ) .</brief_summary>
	<brief_title>90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy Patients With Bulky Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description>The patient limited-stage , bulky diffuse large B cell lymphoma ( DLBCL ) know poor prognosis like advanced disease . However , limited study compare clinical outcome therapy chemotherapy combine modality use radiation . Defining local failure bulky sit one component relapse , radioimmuotherapy appear reduce failure rate previous bulky site . We assess clinical efficacy toxicity 6th R-CHOP chemotherapy follow ibritumomab tiuxetan ( Zevalin ) consolidation patient limited-stage , bulky DLBCL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Newly diagnose CD20+ DLBCL Patients stage I/II Bulky disease define maximum diameter great 10 cm mediastinal mass exceed 1/3 maximum trans thoracic diameter ( 8 cm ) Patients achieved complete ( CR ) partial response ( PR ) 6th RCHOP chemotherapy Aged 18 year ECOG performance status 02 . Previous history chemotherapy diffuse large B cell lymphoma Prior myeloablative therapy Prior externalbeam radiation &gt; 25 % active bone marrow Pregnancy lactation &gt; 25 % bone marrow infiltration Platelet count &lt; 100 000/µl , neutrophil count &lt; 1500/µl Children adolescent 18 year age Presence CNS involvement diffuse large B cell lymphoma Positive HIV serology Seriously uncontrolled , current infection concomitant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>bulky diffuse large B cell lymphoma</keyword>
	<keyword>90Y-ibritumomab tiuxetan</keyword>
	<keyword>clinical response</keyword>
	<keyword>Safety toxicity</keyword>
</DOC>